Company: SXTPW
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001013762-25-003343
Chunk: 1618

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 7
Chunk 1618
---
, focused on the development and marketing of new medicines for the treatment and
prevention of infectious diseases. The determination of a single business segment is consistent with the consolidated financial information
regularly provided to the Company’s chief operating decision maker (“CODM”). 

The Company’s CODM is its Chief Executive
Officer, who reviews and evaluates consolidated net income or loss for purposes of evaluating performance, making operating decisions,
allocating resources, and planning and forecasting for future periods. The significant components of consolidated net income or loss
regularly provided to the CODM include net product revenues and the significant expense categories presented in the accompanying Consolidated
Statements of Operations and Comprehensive Loss (cost of revenues, research and development, and general and administrative expenses).
These are presented at the consolidated level and used by the CODM to monitor budgeted versus actual results to make key operating decisions.
The information and operating expense categories presented in the accompanying Consolidated Statements of Operations and Comprehensive
Loss are fully reflective of the significant expense categories and amounts that are regularly provided to the CODM.

The measure of segment assets that is regularly
reported to the CODM includes cash and cash equivalents and short-term investments, each as reported on the Consolidated Balance Sheets.
Total consolidated cash and cash equivalents and short-term investments were $3,387,825 and $2,142,485 as of December 31, 2024 and December
31, 2023, respectively.

F-14

Revenue Recognition

The Company recognizes revenue in accordance
with FASB ASC Topic No. 606, Revenue from Contracts with Customers (“ASC 606”). Revenues are recognized when control
is transferred to customers in amounts that reflect the consideration the Company expects to be entitled to receive in exchange for those
goods. Revenue recognition is evaluated through the following five steps: (i) identification of the contract, or contracts, with a customer;
(ii) identification of the performance obligations in the contract; (iii) determination of the transaction price; (iv) allocation of
the transaction price to the performance obligations in the contract; and (v) recognition of revenue when or as a performance obligation
is satisfied. As part of the accounting for these arrangements, the Company may be required to make significant judgments, including
identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price
and allocating the transaction price to each performance obligation.

Revenues from product sales are recorded at the
net sales price, or “transaction price,” which may include